Alnylam Pharmaceuticals stock
ALNYNASDAQAlnylam Pharmaceuticals, Inc., HealthcareISIN US02043Q1076
57Score 57 out of 100, Neutral
Price and trend
24 / 100
Price history
−65% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 42% below it.
Since February 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 19).
The price is 66% below its 52-week high. Largest decline in 20 years: 84% (October 2007 to October 2011).
Chart figures for advanced users
- SMA 50$223.45
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$277.36
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)19
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$151.64
- The lowest closing price of the last twelve months.
- Resistance$473.29
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alnylam Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $21.41B, is number 18 of 296 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $5.44B (up 46.4%) and adjusted earnings per share of $18.40 (up 976.3%).
- MEQIRI Score 57 out of 100 (Neutral): rank 315 of 714 in Healthcare, median 53.
Show more
- The P/E is 8.1 (Biotechnology median 21.3, own median of recent years 166.4).
- Our model puts fair value at $336.65, with the price 53% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 49.8% a year since 2020, Biotechnology median 19.7%.Growth 70
- High marginNet margin 54.3% over the last 12 months, Biotechnology median −93.3%.Profitability 98
- Modestly valuedP/E 8.1, Biotechnology median 21.3, own median 166.4.Valuation 92
Weaknesses
- Analysts expect falling earningsDown 23.9% a year through 2028 (estimates from 17 analysts).
- Share price fell sharplyDown 64% over the last 12 months.Momentum 12
- DilutionShare count up 14% since 2020.Capital allocation 51
Its standout strengths are profitability and valuation, while technical analysis and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price far below its 52-week high
- weak fundamentals
- high price swings
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $240.47 and expensive above $561.09 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $253.14 (cash-flow model) and $420.16 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $319.31, at 8.5% it would be $361.35.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 56.2% on the twelve months before. Revenue has grown strongly since 2006, at around 30% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating 14%, net 8%. Last 12 months: net 54%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 29 Oct 2026EPS reported $16.26 (expected $1.66)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 10.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $18.40+176.1%
- Revenue
- $5.44B−0.6%
- Earnings per share
- $8.95−10.6%
- Revenue
- $6.63B−4.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −29.0%Alnylam reiterates its 2026 guidance only formally but now expects the low end of the $4.2 to $4.5 billion TTR revenue range and no growth acceleration in Q4 due to weaker demand, the 340B rule change, and more restrictive Medicare Advantage access.
“For TTR product sales, based on performance to date and our expectations for Q4, we expect to land at the low end of our $4.2 billion-$4.5 billion range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $1.54M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alnylam Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 57
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- WuXi Biologics (Cayman)2269.HK $25.42B73
- United TherapeuticsUTHR $25.37B81
- IncyteINCY $24.92B70
- BioNTechBNTX $21.73B37
- Innovent Biologics1801.HK $19.29B61
- ExelixisEXEL $17.77B90
- Neurocrine BiosciencesNBIX $17.65B77
- Ascendis PharmaASND $17.06B69
ETFs that hold Alnylam Pharmaceuticals
Held by 105 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 1.49% | 0.49% | €26.29M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.38% | 0.35% | €1.21B |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.10% | 0.49% | €318.39M |
Show 5 more
| Amundi US Tech 100 Equal Weight UCITS ETF DR USDWEBA | 0.60% | 0.07% | €340.27M |
| Deka MSCI USA MC UCITS ETFEL41 | 0.43% | 0.30% | €51.58M |
| Amundi Global Gender Equality UCITS ETF AccVOOM | 0.39% | 0.20% | €55.72M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.31% | 0.12% | €1.34B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.30% | 0.18% | €837.43M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Feb 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.